Research programme: WRN inhibitors - Ryvu Therapeutics
Latest Information Update: 30 May 2024
At a glance
- Originator Ryvu Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Werner syndrome helicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 15 May 2024 Preclinical trial in Solid tumours in Poland (unspecified route) before May 2024
- 15 May 2024 Pharmacodynamics data from a preclinical trial in Solid tumors released by Ryvu Therapeutics
- 05 Apr 2024 Pharmacodynamics and pharmacokinetics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)